News & Articles

Impel co-founder and CSO, Dr. John Hoekman, presented today at 11:00 AM on a panel discussing, "What’s New in Alzheimer’s and Other Neurodegenerative Diseases?" at Life Science Innovation Northwest 2018 in Seattle, WA. The panel was moderated by Dr. Adrian Hobden, President & CEO of CereSpir. Dr. John Hoekman was joined by Dr. Leen Kawas, President & CEO...

Impel's CEO, Jon Congleton, CSO, Dr. John Hoekman, and CMO, Dr. Stephen Shrewsbury, will be presenting at Cowen's 38th Annual Health Care Conference in Boston, MA on Wednesday, March 14th from 1:30 - 1:55 PM EDT. For more information, visit www.cowen.com/capabilities/conferences-events. ...

Novel, Intranasal Dihydroergotamine Dosed via Precision Olfactory Delivery, or POD™, Device Achieved Primary Outcome of Bioavailability, Safety Study Marks First of Four Impel Clinical Trial Read Outs Planned for 2018 SEATTLE, Feb. 7, 2018  -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today...

Jon Congleton, Impel's CEO, will be attending the  J.P. Morgan 36th Annual Healthcare Conference in San Francisco, CA from January 8 to 11. For more information, visit: https://www.jpmorgan.com/country/US/EN/jpmorgan/investbk/conferences/healthcare...

New Vice President will build clinical operations department while leading several early stage clinical programs December 12, 2017 -- On December 6th, Impel NeuroPharma, Inc. announced the appointment of seasoned clinical operations leader, Meghan Swardstrom, as Vice President of Clinical Operations. “Impel has made tremendous progress in just twelve months with one...

Study to Explore Bioavailability and Safety of Novel, Intranasal Dihydroergotamine Delivered via Precision Olfactory Delivery™ Technology SEATTLE, October 31, 2017 -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the first patient was dosed in the recently-initiated...

Impel's Co-founder and CSO, Dr. John Hoekman, will be on a panel discussion on Novel Approaches to Alzheimer’s Disease from 10:00 to 10:30 am on Wednesday, October 11 at the Neuro Advance conference in Boston. For more information, visit https://bbbiotechconference.com/conference-agenda.php?id=62...

New CEO will lead Impel’s unique CNS pipeline to the clinic and potential commercialization Seattle, WA—October 03, 2017—Impel NeuroPharma, Inc., a Seattle based biotechnology company, announced the appointment of veteran biotech executive Jon Congleton as the company’s new President and Chief Executive Officer (CEO). Impel is developing first-in-class intranasal drug...

September 13, 2017 -- At the beginning of September, Impel NeuroPharma moved its headquarters to 201 Elliot, a new biotech lab and office building. “The office gives us the capacity to grow, it takes us from startup mode to small company mode.” Dr. John Hoekman, Impel's CEO is quoted as saying...